Eli Lilly And Co (NYSE:LLY) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 12,215,500 shares, an increase of 6.2% from the June 15th total of 11,502,800 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 4,170,000 shares, the short-interest ratio is presently 2.9 days.
Shares of NYSE:LLY traded down $0.03 during trading on Tuesday, reaching $108.69. The company had a trading volume of 4,564,999 shares, compared to its average volume of 9,805,341. The company has a market cap of $105.11 billion, a price-to-earnings ratio of 19.58, a price-to-earnings-growth ratio of 1.92 and a beta of 0.20. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The firm’s fifty day moving average price is $111.20. Eli Lilly And Co has a fifty-two week low of $97.53 and a fifty-two week high of $132.13.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. During the same quarter in the previous year, the company posted $1.31 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
In other news, CFO Joshua L. Smiley purchased 426 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were bought at an average price of $118.03 per share, with a total value of $50,280.78. Following the completion of the transaction, the chief financial officer now directly owns 30,410 shares in the company, valued at approximately $3,589,292.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the transaction, the vice president now directly owns 110,300 shares in the company, valued at approximately $12,874,216. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
Several institutional investors have recently bought and sold shares of LLY. Comerica Securities Inc. increased its stake in shares of Eli Lilly And Co by 80.6% in the 4th quarter. Comerica Securities Inc. now owns 4,154 shares of the company’s stock worth $481,000 after acquiring an additional 1,854 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Eli Lilly And Co by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,070,587 shares of the company’s stock worth $239,597,000 after acquiring an additional 18,958 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Eli Lilly And Co by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 13,108,002 shares of the company’s stock worth $1,514,582,000 after acquiring an additional 830,689 shares in the last quarter. Western Wealth Management LLC bought a new position in shares of Eli Lilly And Co in the 4th quarter worth about $622,000. Finally, Macquarie Group Ltd. increased its stake in shares of Eli Lilly And Co by 14.9% in the 4th quarter. Macquarie Group Ltd. now owns 369,601 shares of the company’s stock worth $42,770,000 after acquiring an additional 47,837 shares in the last quarter. Hedge funds and other institutional investors own 79.50% of the company’s stock.
Several research analysts have commented on LLY shares. Barclays reaffirmed a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a research report on Sunday, April 14th. TheStreet lowered Trade Desk from a “b-” rating to a “c-” rating in a research report on Thursday, May 9th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Edward Jones raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a report on Tuesday, April 23rd. Finally, Zacks Investment Research lowered HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 21st. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $123.49.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.